Almost everything known about CJC-1295 tolerability in people comes from a single 2006 trial in healthy adults. Separately, the FDA has identified serious adverse events for it, including increased heart rate and a systemic vasodilatory reaction, and states the available clinical data are limited.
CJC-1295 side effects fall into three groups: the local reactions any subcutaneous peptide can cause, the downstream effects of raising GH and IGF-1, and the systemic adverse events the FDA has identified. The honest problem underneath all three is the size of the evidence. Human data on CJC-1295 come almost entirely from one 2006 trial in healthy adults [1], and no long-term human safety study exists.
- Local injection-site reactions are the most common issue and match the class pattern for a GHRH analog: redness, itch, and swelling that fade [5]
- Fluid retention, joint aches, and reduced glucose tolerance come from raising GH and IGF-1, not from the peptide itself [5]
- FDA has identified serious adverse events for CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and states clinical data are limited [4]
- Human safety data come from one 2006 trial; the only registered patient trial was terminated in 2006 [1][6]
- A single dose raised basal GH about 7.5-fold while normal pulsatility continued; the long-term effect of chronically raised basal GH is not established [1][2]
- CJC-1295 is prohibited in sport at all times and is not an FDA-approved drug [4][7]
The Side-Effect Data Is One Small Trial
The best human data on CJC-1295 come from a single 2006 study in healthy adults. A dose raised mean plasma GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days, and with repeated dosing IGF-1 stayed above baseline for up to 28 days [1]. Its estimated half-life is 5.8 to 8.1 days [1]. The multi-day duration comes from a group that bioconjugates the peptide to serum albumin [3], which is what keeps CJC-1295 circulating far longer than sermorelin.
That trial was built to measure pharmacology, not to catch rare or long-term harms. The only registered patient trial, a Phase 2 study in HIV-associated visceral obesity, is recorded as terminated in 2006 with no reason stated in the registry [6]. So the side-effect picture below combines what that one trial reported, what the FDA has flagged, and what the nearest FDA-approved GHRH analog documents on its label.
Injection-Site and Local Reactions
Local reactions at the injection site are the most common side effect of any subcutaneous GHRH analog. The nearest FDA-approved GHRH analog reports injection-site reactions in 25% of patients versus 14% on placebo [5]. These are redness, itching, bruising, and small welts that resolve without stopping treatment.
- Redness or warmth at the site, usually within minutes and gone within hours
- Itching or a small raised welt that settles over a day
- Bruising, more likely with a blunted needle or a rushed injection
- Rotating sites and letting the solution reach room temperature reduces the sting
Water Retention, Joint Aches, and Glucose
These effects come from the downstream job of GH and IGF-1, so they scale with how high a protocol pushes those numbers. The approved GHRH analog label documents peripheral edema, arthralgia, and reduced glucose tolerance as class effects of raising GH [5]. Mild fluid retention that shows up as puffy hands or ankles is the version most people notice, and it usually eases when the dose is reduced.
Anyone with prediabetes or diabetes should have glucose watched, because raising GH lowers insulin sensitivity. A prescriber working from labs can catch a rising fasting glucose before it becomes a reason to stop.
The Serious Adverse Events the FDA Identified
This is where CJC-1295 separates from sermorelin in the regulatory record. FDA states it has identified serious adverse events including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited [4]. A systemic vasodilatory reaction means blood vessels widening body-wide, which can present as flushing, a drop in blood pressure, and lightheadedness.
These are not the mild local reactions above. They are the reason the peptide sits on the FDA list of bulk substances flagged as a safety risk in compounding, and the reason a legitimate program keeps a prescriber in the loop rather than shipping vials to a checkout page.
What Is Not Known
The largest gap is long-term human data, and it is a real gap, not a technicality. A study designed to test whether CJC-1295 flattens GH pulses found pulse frequency and magnitude unchanged one week after dosing, while basal GH rose 7.5-fold [2]. Normal pulses continue and the trough between them rises. Whether a chronically raised basal GH level matters over years has never been studied in humans.
The theoretical concern that follows is IGF-1 and cancer, since IGF-1 promotes cell growth and any therapy that raises it inherits that question. No carcinogenicity study of CJC-1295 exists, so the honest answer is that the long-term risk is unquantified rather than reassuringly low. Active malignancy is a clear reason not to use it.
How a Careful Program Lowers the Risk
The controllable risks are managed the same way for every GH-axis peptide. A baseline IGF-1 draw establishes the starting point, a 90-day retest shows the response, and a result above the age-adjusted range is a reason to cut the dose rather than push it. A program that dispenses CJC-1295 without a baseline lab has skipped the one step that keeps IGF-1 out of the range where side effects cluster.
The pharmacy matters too. Compounded peptides are not verified by the FDA for quality before sale, and a 503B outsourcing facility works under manufacturing requirements a 503A pharmacy does not. Ask which fills the prescription and whether a Certificate of Analysis is available for the lot. Anyone subject to anti-doping testing should stop here: CJC-1295 is prohibited at all times under the WADA list [7].
Most of the manageable risk on CJC-1295 comes down to keeping IGF-1 in range, which is impossible without a baseline. SystemLabs tests IGF-1 before prescribing and formulates CJC-1295 on clinical indication, so the dose is set against your labs and retested rather than guessed.
Frequently Asked Questions
What are the side effects of CJC-1295?
The common ones are local injection-site reactions, mild fluid retention, joint aches, and reduced glucose tolerance, all of which track with how much a protocol raises GH and IGF-1 [5]. Separately, the FDA has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction, and notes the clinical data are limited [4].
Does CJC-1295 cause water retention?
Yes, mild fluid retention is one of the more common effects, showing up as puffy hands or ankles. It comes from raising GH and IGF-1 rather than from the peptide directly, matches the peripheral edema documented for the approved GHRH analog, and usually eases when the dose is lowered [5].
Is CJC-1295 safe?
The honest answer is that its safety is not well established. Human data come from one 2006 trial in healthy adults, the only registered patient trial was terminated in 2006, and the FDA lists CJC-1295 among bulk substances flagged as a compounding safety risk, with serious adverse events identified [1][4][6]. It can be used more carefully with a baseline IGF-1 and a 90-day retest, but it is not an FDA-approved drug.
What are the long-term side effects of CJC-1295?
No long-term human study exists, so they are unknown rather than proven safe. A single dose raised basal GH about 7.5-fold while normal pulsatility continued, and whether chronically raised basal GH matters over years has not been studied [2]. Because CJC-1295 raises IGF-1, the theoretical cancer question also has no data behind it, which is why active malignancy is a contraindication.
Does CJC-1295 raise heart rate?
The FDA has identified increased heart rate as one of the serious adverse events for CJC-1295, alongside a systemic vasodilatory reaction that can cause flushing and a drop in blood pressure [4]. Anyone with a cardiovascular condition should raise this directly with a prescriber before starting.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- EGRIFTA SV (tesamorelin) for injection: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- A multicenter, randomized, placebo-controlled, double-blind, phase 2 study to evaluate the efficacy and safety of CJC-1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity ClinicalTrials.gov, 2006. NCT00267527, terminated. https://clinicaltrials.gov/study/NCT00267527
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
